Hybrigenics Raised EUR 2.7 Million in a Private Placement
News Dec 16, 2009
Hybrigenics (ALHYG), a bio-pharmaceutical company, listed on Alternext in Paris, with a focus on research and development of new cancer treatments and specialized in protein interactions, announces the successful closing of a EUR 2.735 million private placement.
A total of 1,094,000 new shares at the price of EUR 2.50 has been issued on December 14, 2009 to several qualified investors based upon the delegation of powers approved by the 16th resolution of the General Meeting held on 29 June 2009 and following an accelerated order book building procedure carried out according to paragraph II of article L.411-2 of the French Financial and Monetary Code. This price represents a discount of 15 percent from the mean of the volume-weighted average prices of the last five trading days prior to the closing of the transaction. Invest Securities was the placement agent and book runner.
The new shares represent 10.5 percent of Hybrigenics' capital before the transaction and 9.5 percent after. They will be traded like the existing shares on Alternext in Paris under the same ticker and code (ALHYG ; ISIN FR0004153930). The registration of the new shares should take place on 17 December 2009.
As a complement to the Yorkville equity line facility put in place in October, the upfront cash raised by this private placement will allow Hybrigenics to actively invest in the preparation of the Phase IIb clinical efficacy trial of inecalcitol in hormone-refractory prostate cancer.
So far, the results of the Phase IIa clinical tolerance study on inecalcitol have been very encouraging, with no sign of toxic hypercalcemia up to the highest tested oral dose of 2 milligrams per day, and a strong presumption of efficacy based on a very high (87 percent) response rate of patients to the combination of standard intravenous Taxotere® and promising oral inecalcitol.
"This private placement has attracted new institutional investors to Hybrigenics' capital, whom I thank for their trust in the prospects of the company. Both the discount, limited to 15 percent, and the dilution of about 10 percent are reasonable and show our respect to the existing shareholders, whom I thank for their continuous support," concludes Rémi Delansorne, Hybrigenics' CEO.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018